Published in Transplantation on June 27, 2007
Actively acquired tolerance of foreign cells. Nature (1953) 19.82
The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am (1987) 7.63
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant (2004) 4.04
Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant (2003) 2.83
Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet (1988) 2.51
Percentiles for body mass index in U.S. children 5 to 17 years of age. J Pediatr (1998) 2.51
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation (2004) 1.82
All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation (2002) 1.58
Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol (1994) 1.55
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr (2006) 1.36
Factors predictive of sustained growth in children after renal transplantation. The North American Pediatric Renal Transplant Cooperative Study. J Pediatr (1993) 1.28
Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy (2001) 1.22
Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation (1997) 1.19
Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery (2004) 1.18
Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation (2003) 1.14
Campath-1H use in pediatric renal transplantation. Am J Transplant (2005) 1.13
Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation (1999) 1.10
Pediatric renal transplantation: a review of the UNOS data. United Network for Organ Sharing. Pediatr Transplant (1997) 1.08
The changing causes of graft loss and death after kidney transplantation. Transplantation (2002) 1.02
Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation (2002) 1.02
Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatr Transplant (2004) 1.02
Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. Transplantation (2001) 0.99
The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation (2004) 0.99
Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation (2005) 0.93
Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation (2004) 0.92
Transplant capillaropathy and transplant glomerulopathy: ultrastructural markers of chronic renal allograft rejection. Nephrol Dial Transplant (2003) 0.88
Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation (2006) 0.85
Is tolerance induction the answer to adolescent non-adherence? Pediatr Transplant (2005) 0.84
Short-term outcomes of Thymoglobulin induction in pediatric renal transplant recipients. Pediatr Nephrol (2002) 0.82
Growth and renal function after steroid-free tacrolimus-based immunosuppression in children with renal transplants. Pediatr Nephrol (2000) 0.81
Prope tolerance: the future of organ transplantation--from the laboratory to the clinic. Transplantation (2004) 0.79
Dendritic cells and the mode of action of anticalcineurinic drugs: an integrating hypothesis. Nephrol Dial Transplant (2003) 0.78
Seven-year experience with rabbit antithymocyte globulin after cardiac transplantation at the Montreal Heart Institute. Transplant Proc (1997) 0.77
Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med (2010) 6.26
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
Production of alpha 1,3-galactosyltransferase-deficient pigs. Science (2002) 3.96
Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation (2005) 3.57
Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation (2002) 3.41
Generation of cloned transgenic pigs rich in omega-3 fatty acids. Nat Biotechnol (2006) 3.07
Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab (2003) 3.01
Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J Pediatr (2004) 2.66
Hyperinsulinemia in african-american children: decreased insulin clearance and increased insulin secretion and its relationship to insulin sensitivity. Diabetes (2002) 2.45
VENO-VENOUS BYPASS WITHOUT SYSTEMIC ANTICOAGULATION IN CANINE AND HUMAN LIVER TRANSPLANTATION. Surg Forum (1983) 2.30
THE USE OF COMBINED PRESERVATION TECHNIQUES FOR EXTENDED STORAGE OF ORTHOTOPIC LIVER HOMOGRAFTS. Surg Gynecol Obstet (1968) 2.20
Use of dexmedetomidine in children after cardiac and thoracic surgery. Pediatr Crit Care Med (2006) 2.01
Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med (2008) 1.97
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg (2005) 1.93
Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. Pediatr Res (2006) 1.81
Youth type 2 diabetes: insulin resistance, beta-cell failure, or both? Diabetes Care (2005) 1.78
The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med (2005) 1.75
Complications of right lobe living donor liver transplantation. J Hepatol (2009) 1.73
Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr (2003) 1.71
Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol (2004) 1.68
Polyomavirus allograft nephropathy: sequential assessment of histologic viral load, tubulitis, and graft function following changes in immunosuppression. Am J Transplant (2003) 1.64
Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation (2008) 1.62
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61
EFFECT OF CYCLOSPORIN ON HEPATIC REGENERATION. Surg Forum (1986) 1.59
Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant (2003) 1.58
The role of education in biostatistical consulting. Stat Med (2007) 1.57
Loop-mediated isothermal amplification assay for rapid detection of common strains of Escherichia coli. J Clin Microbiol (2008) 1.55
Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation. Transplantation (2009) 1.54
Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. Transplantation (2008) 1.52
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation (2003) 1.47
Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients. J Clin Microbiol (2004) 1.46
Functionally important glycosyltransferase gain and loss during catarrhine primate emergence. Proc Natl Acad Sci U S A (2006) 1.46
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 1.43
Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation (2002) 1.43
Early signs of cardiovascular disease in youth with obesity and type 2 diabetes. Diabetes Care (2005) 1.43
Transplantation of en bloc pediatric kidneys when the proximal vascular cuff is too short. Transplantation (2007) 1.42
Proposed live donor nephrectomy complication classification scheme. Transplantation (2006) 1.41
Clinical outcomes associated with induction regimens among retransplant kidney recipients in the United States. Transplantation (2015) 1.39
SUCCESSFUL ORTHOTOPIC TRANSPLANTATION OF LIVER HOMOGRAFTS AFTER EIGHT TO TWENTY-FIVE HOURS PRESERVATION. Surg Forum (1967) 1.37
Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr (2006) 1.36
Promotion of altruistic donation. Transplantation (2009) 1.33
Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation (2005) 1.32
Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 1.30
Immunosuppression: practice and trends. Am J Transplant (2004) 1.28
The pathobiology of polyomavirus infection in man. Adv Exp Med Biol (2006) 1.27
Origin of lymph node-derived lymphocytes in human hepatic allografts. Clin Transpl (1989) 1.24
Quantitation of viral DNA in renal allograft tissue from patients with BK virus nephropathy. Transplantation (2002) 1.23
Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis (2006) 1.23
Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology (2002) 1.21
Phylogenetic analysis of polyomavirus BK sequences. J Virol (2006) 1.19
Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chemother (2006) 1.18
Molecular basis of evolutionary loss of the alpha 1,3-galactosyltransferase gene in higher primates. J Biol Chem (2001) 1.18
Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation (2003) 1.18
Update of PAX2 mutations in renal coloboma syndrome and establishment of a locus-specific database. Hum Mutat (2012) 1.15
Quantitation of DNA of polyomaviruses BK and JC in human kidneys. J Infect Dis (2005) 1.12
Antibody-mediated rejection in kidney transplantation: a review. J Transplant (2012) 1.12
Immunoglobulin G, A, and M responses to BK virus in renal transplantation. Clin Vaccine Immunol (2006) 1.12
OKT3 and viral disease in pediatric liver transplant recipients. Clin Transplant (1991) 1.11
Development of a loop-mediated isothermal amplification assay for rapid detection of BK virus. J Clin Microbiol (2007) 1.11
The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl (2002) 1.11
Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg (2005) 1.10
Single versus en bloc kidney transplantation from pediatric donors less than or equal to 15 kg. Transplantation (2008) 1.08
Pathogenesis and management of polyomavirus infection in transplant recipients. Clin Infect Dis (2002) 1.07
Comorbid conditions in kidney transplantation: association with graft and patient survival. J Am Soc Nephrol (2005) 1.06
Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol (2005) 1.05
Augmenter of liver regeneration: an important intracellular survival factor for hepatocytes. J Hepatol (2008) 1.04
Early urethral (Foley) catheter removal positively affects length of stay after renal transplantation. Transplantation (2007) 1.03
The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant (2005) 1.02
Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation (2010) 1.02
Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation (2012) 1.01
3-Methoxycarbonyl-5-nitrophenyl boronic acid: high affinity diol recognition at neutral pH. Bioorg Med Chem Lett (2004) 1.01
Sphingolipid synthesis via olefin cross metathesis: preparation of a differentially protected building block and application to the synthesis of D-erythro-ceramide. Org Lett (2004) 1.00
Inhibition of Simian Virus 40 replication by targeting the molecular chaperone function and ATPase activity of T antigen. Virus Res (2009) 1.00
Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. Am J Transplant (2005) 1.00
A comparative study of BK and JC virus infections in organ transplant recipients. J Med Virol (2005) 0.99
DNA sequencing of viral capsid protein VP-1 region in patients with BK virus interstitial nephritis. Transplantation (2002) 0.99